Polycyclic Serotonin Receptor Modulators for 5-HT2A Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psychedelic drugs like psilocybin and LSD are hallucinogenic and cardiotoxic, limiting their widespread adoption for treating psychological disorders, and there is a need for non-hallucinogenic and non-cardiotoxic tryptamine-like compounds that can be administered safely at home without medical supervision.
Innovation Solution
Development of novel serotonin receptor modulators, including polycyclic serotonin receptor agonists represented by compounds of Formula I, which are designed to target the 5-HT2A receptor for neuroplasticity without causing hallucinations or cardiac toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psychedelic drugs like psilocybin and LSD are used to treat psychological disorders, then therapeutic effects are achieved through 5-HT2A receptor signaling, but hallucinogenic effects and cardiotoxicity occur due to strong agonistic effects at 5-HT2B receptor
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural modifications at different positions of the tryptamine core. The indole ring substituents (R1-R7 positions) are independently optimized to achieve selective affinity for 5-HT2A receptors while minimizing activation of 5-HT2B receptors. This position-specific structural optimization allows differential interaction with receptor subtypes, producing therapeutic effects without hallucinogenic side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, chain lengths, ring structures, and stereochemistry to modulate receptor selectivity. By changing molecular parameters like adding specific alkyl groups at R4/R5 positions or introducing fused ring systems, the compounds achieve optimized binding profiles that favor 5-HT2A over 5-HT2B receptors, thereby maintaining efficacy while reducing cardiotoxicity.
2Reliability
If tryptamine drugs are administered in clinical settings with medical professionals, then safety is improved through monitoring, but ease of operation deteriorates due to requirement of medical supervision
Solution Approach 1:
The patent converts the potential harm of hallucinogenic effects into a benefit by designing compounds that selectively activate 5-HT2A receptors without causing hallucinations. This selective activation allows the compounds to be administered in controlled settings or even at home under guidance, transforming what would traditionally require intensive clinical monitoring into a more accessible treatment modality while maintaining safety.
3Reliability
If well-known 5-HT2A receptor agonists like psilocin are used, then therapeutic effects are achieved, but cardiotoxicity occurs due to strong agonistic effects at 5-HT2B receptor
Solution Approach 1:
The patent applies segmentation by dividing the tryptamine molecule into distinct functional regions with specific substituent patterns. The indole core provides the essential tryptamine pharmacophore for 5-HT2A binding, while strategically placed substituents at various positions (particularly R4-R7) modulate selectivity. This segmented design allows independent optimization of affinity and selectivity parameters to achieve therapeutic efficacy with minimal cardiotoxicity.
Solution Approach 2:
The patent uses composite structural elements by combining the tryptamine core with various heterocyclic rings, alkyl chains, and substituent groups to create compounds with optimized receptor profiles. These composite structures integrate multiple functional features that work synergistically to enhance 5-HT2A selectivity while reducing 5-HT2B activation, thereby maintaining therapeutic benefits and minimizing cardiotoxic effects.
Data Source
AI summary
Serotonin receptor modulators and methods of making and using the same are disclosed herein.